A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Quiz|Articles|September 4, 2026
OncLive Weekly News Quiz (9/4/2026): Did You Miss Key MPN, Myeloma, and Lung Cancer Updates?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA added another approval for ropeginterferon alfa-2b-njft (Besremi) based on the phase 3 SURPASS-ET trial (NCT04285086). In which myeloproliferative neoplasm is the agent now approved?
Advertisement
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
The combination met its primary end point in the phase 3 SANOVO trial, though full efficacy and safety data have not yet been reported.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.
Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.
Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Advertisement
Advertisement
Trending on OncLive
1
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
2
FDA Grants Breakthrough Therapy Designation to JBS-003 for Radiation De-Escalation in HPV+ Oropharyngeal Cancer
3
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
4
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
5